E-钙黏蛋白与miR-200c在MCF-7/ADR及乳腺癌组织的表达研究

目的探讨乳腺癌耐药株中E-钙黏蛋白（E-cadherin）和miR-200c的表达,以及E-cadherin表达与新辅助化疗疗效的关系。方法应用定量RT-PCR方法检测人乳腺癌细胞株MCF-7和阿霉素耐药株MCF-7/ADR中E-cadherin、Twist1以及miR-200c表达,采用免疫组化法检测82例乳腺癌患者新辅助化疗前组织E-cadherin表达。结果与MCF-7相比,E-cadherin在MCF-7/ADR中表达明显降低（P=0.01）,Twist1在MCF-7/ADR中表达明显升高（P〈0.01）,miR-200c在MCF-7/ADR表达较MCF-7显著下降（P〈0.01）。结论 E-cadherin和miR-200c表达下调参与乳腺癌阿霉素耐药,可能是逆转乳腺癌耐药的潜在治疗靶点。

The expressions of E-cadherin and miR-200c in drug-resistant breast cancer cells MCF-7 / ADR and breast cancer tissues

Objective To recognize the pattern of E-cadherin and miR-200c expressions in drug-resistant breast cancer cells and its correlation to the efficacy of neoadjuvent chemotherapy. Method Expressions of E-cadherin,Twist1,and miR-200c in MCF-7 and MCF-7 / ADR were detected with real-time RT-PCR. Expressions of E-cadherin in breast cancer patients received neoadjuvent chemotherapy was detected with immunohistochemistry. Findings E-cadherin expression was significantly reduced in MCF-7 / ADR as compared to MCF-7（ P = 0. 01） and Twist1 expression was significantly increased in MCF-7 / ADR as compared to MCF-7（ P 0. 01）. Down-regulation of miR-200c in MCF-7 / ADR as compared to MCF-7 was observed（ P 0. 01）. Conclusion Down-regulation of E-cadherin and miR-200c is likely to correlate with adriamycin resistance in breast cancer and may possibly serve as potential therapeutic targets for reversing drug resistance in breast cancer.